



LION

L E I P Z I G
IMMUNE ONCOLOGY

CONFERENCE


2024

Leipzig, Germany
November 12–13, 2024

PROGRAM


Organized by





CAR-T-Cell-Therapy ,Made in Leipzig‘

CAR-T-cell-therapy can change lives, and Leipzig's life science ecosystem offers the expertise and networks to make that happen. Here in the heart of Europe, you'll get support from highly specialized clinics, research institutes, and future clusters – so that your cell and gene therapies make it from the lab bench to successful clinical application. We look forward to welcoming you to our community of Life Changers. Discover what Leipzig has to offer and come get to know us in person here:



[Leipzig-for-lifechangers.com](https://leipzig-for-lifechangers.com)

TABLE OF CONTENTS

General information	4
Site plan	8
Program	
Tuesday, November 12, 2024	9
Wednesday, November 13, 2024	14
Posters	19
Sponsors & exhibitors	25
Media partners	27

GENERAL INFORMATION

VENUE

Fraunhofer Institute for Cell Therapy and Immunology
Perlickstraße 1, 04103 Leipzig

REGISTRATION COUNTER

Opening hours

Tuesday, November 12, 2024: 9:00 am – 6:30 pm

Wednesday, November 13, 2024: 8:30 am – 4:00 pm

Contact

Email: tbaehr@eventlab.org
kbornschein@eventlab.org
Phone: +49 341 308884-89 or -82

USEFUL CONTACTS

Leipzig taxis: +49 341 4884
www.taxi4884.de
City Taxi Leipzig: +49 341 2222 4444

WIFI

WiFi is available throughout the building. Look out for the access code.

MEDIA CHECK

Please bring your presentation on a USB stick to the technical support in the lecture room at least 15 minutes before the session. Please note that the presentation must be provided in a Windows / MS Office compatible format.

POSTER SESSIONS

Don't miss our poster sessions on Tuesday, November 12, 2024.

Session I: 11:45 am – 12:45 pm (Location: 2nd floor)

Session II: 4:00–5:00 pm (Location: 1st floor)

Please drop off your poster at the registration desk. We will take care of the mounting. You can remove your poster at the end of the conference. Posters that are not removed will be disposed.

GET-TOGETHER

We are happy to welcome you to the get-together and enjoying a great evening with all participants. You will then also have time to have good talks with the supporters.

Delicious food and drinks will await you as well.

Date: Tuesday, November 12, 2024

Time: From 7:00 pm

GENERAL INFORMATION

SCIENTIFIC ORGANIZING COMMITTEE

Köhl, Ulrike (Conference president)

Fraunhofer Institute for Cell Therapy and Immunology /
University Medicine Leipzig, Leipzig, Germany

Lordick, Florian (Conference president)

University Medicine Leipzig, Leipzig, Germany

Platzbecker, Uwe (Conference president)

University Medicine Leipzig, Leipzig, Germany

Blache, Ulrich

Fraunhofer IZI

Engeland, Christine

University Medicine Leipzig

Fricke, Stephan

Fraunhofer IZI

Herling, Marco

University Medicine Leipzig

Merz, Maximilian

University Medicine Leipzig

Schmiedel, Dominik

Fraunhofer IZI

Schmid, Thomas

Fraunhofer IZI

Tretbar, Sandy

Fraunhofer IZI

Vucinic, Vladan

University Medicine Leipzig

KEYNOTE SPEAKERS

Alici, Evren

Karolinska Institutet, Stockholm, Sweden

Bentler, Martin

Hannover Medical School, Hannover, Germany

Janjigian, Yelena

Memorial Sloan Kettering Cancer Center, New York, USA

Mandelboim, Ofer

The Hebrew University of Jerusalem, Jerusalem, Israel

Moser, Tobias

Georg August University Göttingen, Göttingen, Germany

Qasim, Waseem

University College London, London, UK

Schiffelers, Raymond

University Medical Center Utrecht, Utrecht, The Netherlands

Schirmacher, Peter

Heidelberg University Hospital, Heidelberg, Germany


Sureda, Anna

Catalan Institute of Oncology, Barcelona, Spain

Tsukerman, Pini

Nectin Therapeutics Ltd, Jerusalem, Israel

SITE PLAN



Ground floor

- A – Registration
- B – Lecture hall
- C – Exhibition
- D – Catering
- E – Stairs
- F – Lift
- G – Restrooms
- H – Cloakroom

First / second floor

The poster exhibition will take place on the 1st and 2nd floor.

PROGRAM

TUESDAY, NOVEMBER 12, 2024

9:45–
10:00 am **Welcome**

10:00–
11:30 am

Session I

Chair: Fricke, Stephan & Bornhäuser, Martin

Cellular therapy in lymphoma

 **Keynote** Sureda, Anna (Catalan Institute of Oncology, Barcelona, Spain)

Efficacy of "universal" CAR-T cells in a humanised model of primary CD7+CD33+ acute myeloid leukemia

Kloos, Arnold

Targeted modulation of the NKG2D axis to trigger anti-leukemia and anti-lymphoma NK cell & T cell responses

Winterberg, Dorothee

Endothelial dysfunction and hyperinflammation is linked with severe hematotoxicity after CAR-T therapy

Alb, Miriam (Part of the ImSavar consortium)

11:30–
11:45 am

Break

PROGRAM

TUESDAY, NOVEMBER 12, 2024

11:45 am –
12:45 pm

Poster session I

Chairs: Platzbecker, Uwe &
Ivics, Zoltan & Bornhäuser, Martin

Location: 2nd floor

More information on page 19.

12:45–
1:30 pm

Break

1:30–
2:15 pm

Johnson & Johnson industry symposium "CAR-T cells"

Supported by Johnson & Johnson

Johnson & Johnson

Novel technologies for T cell directing targets

Abken, Hinrich (RCI – University of
Regensburg, Regensburg, Germany)

Management of toxicities and patient selection of CAR-T cell therapies

Fricke, Stephan (Klinikum Chemnitz,
Chemnitz / Fraunhofer IZI, Leipzig,
Germany)

2:15–
2:30 pm

Break

2:30–
4:00 pm

Session II

Chairs: Köhl, Ulrike & Ullrich, Evelyn

NK cell research and transfer towards cancer immuno therapy

 **Keynote** Mandelboim, Ofer (The Hebrew University of Jerusalem, Jerusalem, Israel)

Clinical experiences on NK cell based cancer immuno therapy

 **Keynote** Alici, Evren (Karolinska Institutet, Stockholm, Sweden)

Off-the-shelf chimeric antigen receptor-modified natural killer cells to target cervical cancer and the tumor microenvironment

Polten, Robert

Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss

Eitler, Jiri

PROGRAM

TUESDAY, NOVEMBER 12, 2024

4:00–
5:00 pm

Poster session II

Chairs: Lordick, Florian & Köhl, Ulrike & Ullrich, Evelyn

Location: 1st floor

More information on page 22.

5:00–
7:00 pm

Session III

Chairs: Lordick, Florian & Schmiedel, Dominik

Immune landscape of liver cancer

 **Keynote** Schirmacher, Peter
(Heidelberg University Hospital,
Heidelberg, Germany)

Immunotherapy for upper gastrointestinal cancers

 **Keynote** Janjigian, Yelena (Memorial
Sloan Kettering Cancer Center, New York,
USA)

 Virtual

NTX1088: Pioneering the future of immuno-oncology through PVR blockade

 **Keynote** Tsukerman, Pini (Nectin
Therapeutics Ltd, Jerusalem, Israel)

CD109 as a target for lung cancer and tumor-associated macrophages

Haesen, Tine (Part of the ImSavar consortium)

NK cell engagers targeting NKp30 and epidermal growth factor receptor (EGFR) on solid tumor cells induce potent lysis and pro-inflammatory cytokine release

Klausz, Katja

7:00 pm

Get-together

PROGRAM

WEDNESDAY, NOVEMBER 13, 2024

9:00–
9:45 am

Gilead industry symposium
"Explore the future role of CAR T in addressing unmet needs in 1L DLBCL"

Supported by Gilead Sciences GmbH



GILEAD



**Future Role of CAR T in Addressing
Unmet Needs in 1L DLBCL**

Anna Ossami Saidy (Helios Klinikum
Berlin-Buch, Berlin, Germany)

**Innovations in CAR T Design and
Manufacturing**

Ioana Kloos (Kite Pharma)

**Discussion on how CAR T therapy
management is evolving and
highlighting innovations in design and
manufacturing**

Fricke, Stephan (Klinikum Chemnitz,
Chemnitz / Fraunhofer IZI, Leipzig,
Germany), Anna Ossami Saidy (Helios
Klinikum Berlin-Buch, Berlin, Germany),
Ioana Kloos (Kite Pharma)

9:45–
10:00 am

Break

10:00–
11:15 am

Session IV

Chairs: Schmid, Thomas & Köhl, Ulrike

AAV vectors for cancer gene therapy

 **Keynote** Bentler, Martin (Hannover Medical School)

Lessons learned from AAV-mediated optogenetic hearing restoration

 **Keynote** Moser, Tobias (Georgn August University Göttingen, Göttingen, Germany)

Quality by Design for AAV process development

Schmid, Thomas

11:15–
11:45 am

Break

PROGRAM

WEDNESDAY, NOVEMBER 13, 2024

11:45 am –
12:30 pm

**Astra Zeneca industry
symposium "Advancing
immunotherapy in GI cancers
and haematology"**

Supported by AstraZeneca



**The ABC of GI-oncology: ADCs,
bispecifics & CAR-T**

Lordick, Florian (University Medicine
Leipzig, Leipzig, Germany)

Targeting CD19 beyond CAR-T

Topp, Max (University Hospital of
Würzburg, Würzburg, Germany)

12:30 –
1:15 pm

Break

1:15 –
2:00 pm

**Bristol Myers Squibb Industrie-
symposium "Langzeiterfolge
durch Immuntherapie in der
Tumorkontrolle beim NSCLC
und bei GI Tumoren"**

supported by Bristol-Myers Squibb
GmbH & Co. KGaA



 **Langzeiterfolge bei GI-Tumoren –
IO Kombinationstherapien im
Fokus**

Lordick, Florian (Universitätsmedizin
Leipzig, Leipzig, Deutschland)

 **Doppelimmuntherapie bei NSCLC:
Langzeiterfolge und praxisnahe
Einblicke**

Wolf, Martin (Klinikum Kassel, Kassel,
Deutschland)

2:00 –
2:15 pm

Break

PROGRAM

WEDNESDAY, NOVEMBER 13, 2024

2:15–
4:00 pm

Session V

Chairs: Ivics, Zoltan & Tretbar, Sandy

CRISPR and base edited T cells

 **Keynote** Qasim, Waseem (University College London, London, UK)

Nonviral gene and RNA delivery in the context of immunotherapies

 **Keynote** Schiffelers, Raymond (University Medical Center Utrecht, Utrecht, The Netherlands)

Single-cell multiomic dissection of toxicity and response to BCMA-directed CAR T cells

Rade, Michael

Zebrafish as a novel in vivo model to assess CAR-NK cell efficacy against metastatic breast cancer

Murali Shankar, Nivedha

Innovative approaches to improve nonclinical safety assessment of CAR-T cells and immunomodulatory biotherapeutics: The imSAVAR project

Alb, Miriam (Part of the ImSavar consortium)

POSTERS

Poster session I

Poster session I will take place on Tuesday,

November 12, 2024, 11:45 am – 12:45 pm.

Location: 2nd floor

- P1-01 CAR-NK cell therapies for treatment of severe autoimmune diseases**
Arriens, Marieke
- P1-02 Synthesis and biological evaluation of histone deacetylase inhibitors for more effective CAR-T cell therapy**
Bauer, Leoni
- P1-03 A novel NK cell expansion method using a multifunctional fusion protein for the development of cell-based immunotherapies**
Peipp, Matthias
- P1-04 Shifting gears in CAR T cell manufacturing: LNPs and AAVs as in vivo solutions**
Cetin, Ela
- P1-05 Continuously monitored NK-killing assays for kinetic evaluation of primary subpopulations**
Chen, Po-Chun
- P1-06 Anti-CD123-CAR-NK-92 cells reduce monocyte population in human blood – a potential risk of infection susceptibility for the patient?**
Dehmel, Susann

POSTERS

- P1-07 **Scaling up mRNA-based CAR-T cell manufacturing using lipid nanoparticles**
Gebhardt, Clara
- P1-08 **CD123- and CD33-targeting primary CAR-NK cell preparations for treatment of acute myeloid leukemia**
Gierschek, Fenja
- P1-09 **Towards scalable allogeneic CAR-T manufacturing: Perfusion optimisation and multi-litre scale-up in single-use stirred-tank bioreactors**
Hengst, Julia
- P1-10 **Optimized scRNA-Seq omics workflow for high-resolution CAR T cell profiling**
Kuhn, Christina
- P1-11 **Ex vivo modification of hematopoietic cell transplants in GvHD prevention: Single treatment with the anti-human CD4 antibody MAX.16H5 can outperform state-of-the-art immunosuppressants**
Roth, Kristina
- P1-12 **Automated clinical-grade manufacturing of CAR-NK cells using BaEV-LV on CliniMACS Prodigy**
Sarisoy, Cem

-
- P1-13 **Accelerating innovation in chimeric antigen receptors: Harnessing mRNA for rapid screening**
Serfling, Robert
- P1-14 **Identification and classification of CAR vector insertion sites using long-read DNA sequencing**
Weich, Adrian
- P1-15 **Establishing a modular microfluidic organ-on-chip system for cells of acute myeloid leukemia**
Aerchlimann, Keshia
- P1-16 **Induction of T-cells senescence in the leukemic microenvironment**
Trombello, Lidia
- P1-17 **GMP-compliant up-scaling of an optimized feeder-free NK cell expansion protocol**
Dünkel, Anna
- P1-18 **Advancing cancer immunotherapy: Lipid nanoparticle-mediated mRNA delivery for ex vivo engineering of anti-CD123 CAR-NK cells**
von Auw, Nadine

POSTERS

Poster session II

Poster session I will take place on Tuesday,
November 12, 2024, 4:00–5:00 pm.

Location: 1st floor


- P2-01 Modulation of CD8 T cell responses at the human ex vivo tumor front**
Bargmann, Tonia (Part of the ImSavar consortium)
- P2-02 Interleukin-2 induces type 2 and 17 skin inflammation in a CD25-dependent manner**
Sommer, Charline (Part of the ImSavar consortium)
- P2-03 Immune competent 3D pancreatic adenocarcinoma (PDAC) organoid-on-chip model for preclinical drug testing**
Deipenbrock, Alina
- P2-04 Beyond expression: A novel platform for massively parallel and sequential assaying of single cell function**
Dow, David
- P2-05 Immune cells play a critical role in cytokine- and endotoxin-mediated endothelial permeability**
Goges, Patricia (Part of the ImSavar consortium)

- P2-06 Looking for stable neo-antigens across different splice factor-mutated malignancies**
Güse, Esther
- P2-07 LEDGF/p75 - a possible prognostic biomarker candidate for colorectal cancer?**
Liedtke, Victoria
- P2-08 Ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy**
Lischer, Christopher
- P2-09 Transforming cancer therapy: The essential role of specialized CROs in immuno-oncology**
Mund, Birgit
- P2-10 Pd(II) coumarin complexes as potential agents against breast carcinoma**
Pecić, Katarina
- P2-11 Interleukin-2 dynamically reduces interleukin-2 receptor β expression and function especially in T cells**
Sommer, Charline (Part of the ImSavar consortium)
- P2-12 From solo to duet: Combining CAR-modified immune cells for efficient cancer immunotherapy**
Silva Ferreira, Francisca

POSTERS

- P2-13 **Quantitative profiling of MHC class I and class II antigens and neoantigens for discovery and targeted applications using an optimized mass spectrometry-based workflow**
Stefanoska, Despina
- P2-14 **Promoting long-term persistence and efficacy of CAR-T cells and adoptive cellular products by the restoration of their autophagy machinery**
Haas, Dorothee
- P2-15 **CAR T cell-mediated cytotoxicity and cytokine release in response to varying levels of antigen expression on target cells and production methods**
Yu, Zhong
- P2-16 **Breast cancer-on-chip model for efficacy and safety testing of CAR-T cells**
Teufel, Claudia (Part of the ImSavar consortium)
- P2-17 **A Prototype approach for the detection of spectral data using 88-channel detection system and a cytoFLEX LX flow cytometer**
Listoshin, Slava

SPONSORS & EXHIBITORS



Exhibitor	Booth
AbbVie Deutschland GmbH & Co. KG	8
Amgen GmbH	12
Astellas Pharma GmbH	11
AstraZeneca GmbH	16
Avantor	1
Beckman Coulter Life Sciences	14
BeiGene Germany GmbH	13
Bristol-Myers Squibb GmbH & Co. KGaA	6
Gilead Sciences GmbH	15
Johnson&Johnson Innovative Medicine	10
Janvier Labs	9
Lilly Deutschland GmbH	2
Novartis Pharma GmbH	5
OMNI Life Science GmbH & Co. KG	4
VectorBuilder GmbH	7
Zymo Research Europe GmbH	3

SPONSORS & EXHIBITORS



We disclose the financial support of all sponsors on the conference homepage at www.lion-conference.com/sponsors-exhibitors.php

MEDIA PARTNERS

A white silhouette of a person's head in profile, facing right, is positioned on the left side of the lower half of the image.

SEE YOU NEXT TIME.

In Leipzig, Germany.

AAV MEETING

LEIPZIG | APRIL 1–2, 2025

FROM LAB TO CLINIC

**All AAV researchers are
invited to submit abstracts.**

**ABSTRACT
DEADLINE**

JANUARY 20, 2025

**PARTICIPATION
IS FREE
OF CHARGE**

SESSIONS & KEYNOTES

Medical potential / clinical experiences

Hildegard Büning (Hannover
Medical School)

Tobias Moser (University Medical
Center Göttingen)

William Nyberg (Karolinska
Institutet)

Pitfalls from lab scale to GMP

Thomas Schmid & Jacqueline
Breuer (Fraunhofer IZI)

Quality by design

Michael Bortz (Fraunhofer ITWM)

Manufacturing

Eduard Ayuso (DINAMIQS)

Regulatory and funding

Martina Schüssler-Lenz
(Paul-Ehrlich-Institut)

Stephan Junker (Eurogrant
GmbH)

www.AAV-meeting.com